Premium
Cost‐effectiveness analysis of TNF‐α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health‐care system
Author(s) -
Portu Simona de,
Giglio Micol Del,
Altomare Gianfranco,
Arcangeli Fabio,
Berardesca Enzo,
Calzavara Pinton Piergiacomo,
Lotti Torello,
Martini Patrizia,
Peserico Andrea,
Simonacci Marco,
Vena Gino A.,
Girolomoni Giampiero
Publication year - 2010
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2009.01280.x
Subject(s) - etanercept , infliximab , medicine , dermatology life quality index , psoriasis , adalimumab , psoriasis area and severity index , quality of life (healthcare) , cost effectiveness , randomized controlled trial , dermatology , physical therapy , surgery , tumor necrosis factor alpha , nursing , risk analysis (engineering)
ABSTRACT The cost‐effectiveness of biological treatments for psoriasis is not well determined and may vary from country to country. The objectives of this study was to perform a cost‐effectiveness analysis of infliximab compared with other anti‐tumor necrosis factor‐α agents for the treatment of psoriasis in Italy. The incremental cost‐effectiveness ratio per patients achieving at least 75% improvement in the psoriasis area and severity index assessed over 24‐ and 48–50‐week periods was calculated. Efficacy data were drawn from randomized controlled trials when available or from open label studies. Considering patients achieving psoriasis area and severity index at week 24 and 48–50, infliximab was dominant (more effective and less costly) over etanercept given at 50 mg twice weekly. In contrast, infliximab was not dominant over etanercept at other dosages or over adalimumab. When considering the impact of therapy on quality of life at Week 12 using the Dermatology Life Quality Index equal to zero, infliximab resulted more effective and less costly than etanercept. Therefore, infliximab seems to be cost‐effective in the therapy of psoriasis. Further cost‐efficacy evaluations based on head‐to‐head trials are necessary to address health economic considerations.